A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: A report of the European Anti- ICAM-1 Renal Transplant Study group

Transplantation

Volumn 67, Issue 5, 1999, Pages 729-736

  Salmela, Kaija ^a   Wramner, Lars ^b   Ekberg, Henrik ^c   Hauser, Ingeborg ^d   Bentdal, Øystein ^e   Lins, Lars Eric ^f   Isoniemi, Helena ^a   Bäckman, Lars ^b   Persson, Nils ^c   Neumayer, Hans Hellmut ^d   Jørgensen, PäL Foyn ^e   Spieker, Claus ^g   Hendry, Bruce ^h   Nicholls, Anthony ⁱ   Kirste, Günter ^j   Hasche, Georg ^k  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f Boehringer Ingelheim AB   (Sweden)

^g Raphaels Klinik Munster GmbH   (Germany)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^j UNIVERSITY OF FREIBURG   (Germany)

^k KATHARINENHOSPITAL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; INTERCELLULAR ADHESION MOLECULE 1; MONOCLONAL ANTIBODY; PREDNISOLONE;

ADOLESCENT; ADULT; AGED; ARTICLE; CADAVER KIDNEY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

EID: 0033559042     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199903150-00015     Document Type: Article

References (37)

1. Gulaniker AC, MacDonald AS, Sungurtekin U, Belitsky P. The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants. Transplantation 1992; 53: 323.
2. Almond PS, Matas AJ, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752.
3. Tesi RJ, Henry ML, Elkammas EA, Ferguson RM. Predictors of long-term primary cadaveric renal transplant survival. Clin Transpl 1993; 7: 345.
4. Halloran PF, Aprile MA, Farewell V, et al. Early function as the principal correlate of graft survival. Transplantation 1988; 46: 223.
5. Mihatsch MJ, Ryffel B, Gudat T, et al. Cyclosporine nephropathy. In: Tisher CC, Brenner BM, eds. Renal pathology. Philadelphia: Lippincott, 1989.
6. Clark KR, Forsythe JLR, Shenton BK, Lennard TWJ, Proud G, Taylor RMR. Administration of ATG according to the absolute T lymhocyte count during therapy for steroid-resistant rejection. Transpl Int 1993; 6: 18.
7. Bock HA, Gallanti H, Zurcher RM, et al. A randomized prospective trial of prophylactic immunosuppression with ATG-Fresenius versus OKT3 after renal transplantation. Transplantation 1995; 59: 830.
8. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
9. Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med 1994; 331: 365.
10. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301.
11. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994; 84: 2068.
12. Tedder TF, Steeber DA, Chen A, Engel P. The selectins: vascular adhesion molecules. FASEB J 1995; 9: 866.
13. Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA. Induction by IL-1 and interferon-γ: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAm-1). J Immunol 1986; 137: 245.
14. Osborn L. Leukocyte adhesion to endothelium in inflammation Cell 1990; 62: 3.
15. Damle NK, Klussman K, Linsley PS, Aruffo A. Differential costimulatory effects of adhesion molecules B7, ICAm-1, LFA-3 and VCAm-1 on resting and antigen-primed CD4-T lymphocytes. J Immunol 1992; 148: 1985.
16. Fuggle SV, Sanderson JB, Gray DWR, Richardson A, Morris PJ. Variation in expression of endothelial adhesion molecules in pretransplant and transplanted kidneys: correlation with intragraft events. Transplantation 1993; 55: 117.
17. Brockmeyer C, Ulbrecht M, Schendel DJ, et al. Distribution of adhesion molecules (ICAm-1, VCAm-1, ELAm-1) in renal tissue during allograft rejection. Transplantation 1993; 55: 610.
18. Briscoe DM, Pober JS, Harmon WE, Cotran RS. Expression of vascular cell adhesion molecule-1 in human renal allografts. J Am Soc Nephrol 1992; 3: 1180.
19. Hill PA, Main IW, Atkins RC. ICAm-1 and VCAm-1 in human renal allograft rejection. Kidney Int 1995; 47: 1383.
20. Von Willebrand E, Lautenschlager I, Krogerus L, Häyry P, Isoniemi H, Salmela K. Adhesion molecules and activation markers in acute rejection of human renal allografts. Transpl Immunol 1996; 57.
21. Hauser IA, Riess R, Hausknecht B, Thüringer H, Sterzel RB. Expression of cell adhesion molecules in primary renal disease and renal allograft rejection. Nephrol Dial Transplant 1997; 12: 1122.
22. Investigator's Drug Brochure, Boehringer Ingelheim; August 1993.
23. Cosimi AB, Conti D, Delmonico FL, et al. In vivo effects of monoclonal antibody to ICAm-1 (CD54) in non-human primates with renal allografts. J Immunol 1990; 144: 4604.
24. Haug CE, Colvin RB, Delmonico FL, et al. A phase I trial of immunosuppression with anti-ICAm-1 (CD54) mAb in renal allograft recipients. Transplantation 1993; 55: 766.
25. Tolkoff-Rubin N, Rothlein R, Scharschmidt L, et al. Immunosuppression with Anti-ICAm-1 (CD-54) MAB in renal allograft recipients. J Am Soc Nephrol 1991; 2: 820.
26. Sykes M. Immunobiology of transplantation. FASEB J 1996; 10: 721.
27. Rabb H, Mendiola CC, Saba SR, et al. Antibodies to ICAm-1 protect kidneys in severe ischemic reperfusion injury. Biochem Biophys Res Commun 1995; 211: 67.
28. Kelly KJ, Wiliams WW Jr, Colvin RB, et al. Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest 1996; 97: 1056.
29. Haller H, Dragun D, Miethke A, et al. Antisense oligonucleotides for ICAm-1 attenuate reperfusion injury and renal failure in the rat. Kidney Int 1996; 50: 473.
30. Hauser IA, Johnson DR, Madri JA. Differential induction of VCAm-1 on human iliac venous and arterial endothelial cells and its role in adhesion. J Immunol 1993; 151: 5172.
31. Hourmant M, Bedrossian J, Durand D, et al. A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations. Transplantation 1996; 62: 1565.
32. Takada M, Nadeau KC, Shaw GD, Marquette KA, Tilney NL. The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney. J Clin Invest 1997; 99: 2682.
33. Vincenti F, Lantz M, Birnbaum J, et al. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. Transplantation 1997; 63: 33.
34. Soulillou JP, Cantarovich D, LeMauff B, et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts N Engl J Med 1990; 322: 1175.
35. Montano RF, Romano L. Human monoclonal anti-RH antibodies produced by human-mouse heterohybridomas express the Gal α1-3 Gal epitope. Hum Antibod Hybridomas 1994; 5: 152.
36. Opelz G. Efficacy of rejection prophylaxis with OKT3 in renal transplantation: collaborative transplant study. Transplantation 1995; 60: 1220.
37. Abramowicz D, Norman DJ, Vereerstraeten P, et al. OKT 3 prophylaxis in renal grafts with prolonged cold ischemia times: association with improvement in long-term survival. Kidney Int 1996; 49: 768.